China Spinal Cord Injury Network
11
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
13%
1 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Feasibility and Safety of Umbilical Cord Blood Transfusion in the Treatment of Neonatal Cerebral Ischemia and Anemia
Role: collaborator
Safety and Feasibility Study of Umbilical Cord Blood Mononuclear Cells Transplant to Treat Ischemic Stroke
Role: lead
Treatment for Chronic Spinal Cord Injury: Surgery With Rehabilitation vs Rehabilitation
Role: collaborator
Study to Evaluate the Efficacy of Lithium Carbonate in Spinal Cord Injury Patients With Neuropathic Pain
Role: lead
A Multi-Centre Clinical Study in Spinal Cord Injury Patients in Mainland China and Hong Kong
Role: lead
Efficacy and Safety of Lithium Carbonate in the Treatment of Chronic Spinal Cord Injuries
Role: lead
Umbilical Cord Blood Mononuclear Cell Transplant to Treat Chronic Spinal Cord Injury
Role: lead
Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord
Role: lead
Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury
Role: lead
Safety and Pharmacokinetics Study of Oral Lithium in Patients With Chronic Spinal Cord Injury
Role: collaborator
A Multi-Centre Clinical Study in Chronic Spinal Cord Injury Patients
Role: lead
All 11 trials loaded